Article
BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 May 2014
Toon Christopher W, Chou Angela, DeSilva Keshani, Chan Joseph, Patterson Jillian, Clarkson Adele, Sioson Loretta, Jankova Lucy, Gill Anthony J
Abstract excerpt
Immunohistochemistry has recently been validated for the detection of the BRAFV600E mutation across a range of tumor types. In colorectal carcinoma, the presence of the BRAFV600E mutation can be used to virtually exclude Lynch syndrome in mismatch repair-deficient tumors. In mismatch repair-proficient tumors, BRAFV600E mutation assessed by molecular methods has been proposed as a poor prognostic factor. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
